Navigation Links
DelMar Pharmaceuticals Gives Quarterly Shareholder Update
Date:11/11/2013

VANCOUVER, British Columbia and MENLO PARK, Calif., Nov. 11, 2013 /PRNewswire/ -- Dear Shareholders and Friends of DelMar Pharmaceuticals:

I am pleased to provide you with an update as of the quarter ended September 30, 2013 and a summary of progress toward our goals for the year.

Our Financials Are on Budget
As of September 30, 2013 we have cash and equivalents of approximately $5.2 million.  Our working capital balance is in line with our expectations.  Based on our operating budget, we estimate that these funds will provide us with sufficient capital to support our ongoing research and development activities for the next 18 months.  We continue to explore options for funding to finance further research beyond that date.

Details of our quarterly financials can be found via the SEC Filings section of our website at:  http://www.delmarpharma.com/investors/sec_filings/.

We Are Making Continued Progress with VAL-083 Clinical Trials in Brain Cancer  
VAL-083 was studied in more than 40 historical human clinical trials sponsored by the National Cancer Institutes (NCI) in the United States and is approved as a cancer chemotherapy in China for the treatment of both chronic myelogenous leukemia (CML) and lung cancer.  Historical data suggests that VAL-083 has activity against a broad range of tumor types, including glioblastoma multiforme (GBM) the most common and aggressive form of brain cancer, for which there are currently limited treatment options.

Our business model focuses on identifying well-validated clinical and commercial-stage compounds and establishing a scientific rationale for development in modern orphan cancer indications.  To this aim, we are currently conducting a Phase
'/>"/>

SOURCE DelMar Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. DelMar Pharmaceuticals Presents Data Supporting VAL-083 as a Potential Treatment for Three Chemotherapy Resistant Cancers
2. DelMar Pharma reviews glioblastoma clinical trials and new therapeutic development on CEOLIVE.TV
3. DelMar Pharmaceuticals and Guangxi Wuzhou Pharmaceuticals Establish Clinical Advisory Board in China
4. DelMar Pharmaceuticals To Present At The 15th Annual Rodman & Renshaw Global Investment Conference
5. DelMar Pharmaceuticals, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
6. DelMar Pharmaceuticals Presents Additional Clinical Data from Ongoing Brain Cancer Study at ASCO
7. DelMar Pharmaceuticals, Inc. to Webcast, Live, at RetailInvestorConferences.com June 6th
8. DelMar Pharmaceuticals to Present Clinical Trials Data for VAL-083 Brain Cancer Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting
9. DelMar Pharmaceuticals, Inc. Provides Corporate Update for the Quarter Ended March 31, 2013
10. DelMar Pharma Presents Encouraging Data From Ongoing Phase I/II GBM Clinical Trial With VAL-083
11. DelMar Pharmaceuticals to Present Clinical Data from VAL-083 Brain Cancer Trial at the American Association of Cancer Research Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015 Research and Markets ... the "Urinary Catheters Market (Indwelling or Foley Catheters, ... Global Industry Analysis, Size, Share, Growth, Trends and Forecast ... , At present, the global market for ...
(Date:1/23/2015)... Inc. (NASDAQ: NWBO )("NW Bio"), a U.S. biotechnology ... solid tumor cancers, announced today that CEO Linda Powers ... Immunotherapy Forum in Washington D.C. ... January 26 at 10:30 a.m. EST at the Grand Hyatt ...
(Date:1/23/2015)... and DUBLIN , Jan. 23, 2015 ... with KRS Global Biotechnology, Inc. for the compounding, packaging and ... for shipment in the United States . ... Outsourcing Facility capable of compounding naltrexone tablets in various strengths ...
Breaking Medicine Technology:Urinary Catheters Market (Indwelling or Foley Catheters, Intermittent Catheters and Male External or Condom Catheters) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Urinary Catheters Market (Indwelling or Foley Catheters, Intermittent Catheters and Male External or Condom Catheters) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 2NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 4
... THE WOODLANDS, Texas, Nov. 22, 2011 OncologyRx Care ... specialty pharmacy, has been selected by Incyte Corporation ...  pharmacies across the U.S. authorized to fill prescriptions for ... Myelofibrosis (MF) patients.   (Logo:  ...
... Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ... Administration (FDA) has accepted for review the Company,s supplemental ... Use for the prevention of gout flares in patients ... Fee Act (PDUFA), the goal for a standard review ...
Cached Medicine Technology:OncologyRx Care Advantage™ Chosen to Fill Prescriptions for Jakafi™ (ruxolitinib) 2Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review 2Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review 3Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review 4Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review 5Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review 6Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review 7Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review 8
(Date:1/22/2015)... Chemo Duck Program is pleased to announce the release of the ... with cancer. The Chemo Duck App, available on iTunes for use ... to help children of all ages living with cancer adjust to ... entertained, educated and at ease while waiting for clinic visits or ...
(Date:1/22/2015)... Angelweddingdress is a famous wedding dress company offering many trendy ... on Facebook, Twitter, and Pinterest. The fans will have an ... lottery every week. , Moreover, the company has extended its ... Angelweddingdress homepage for more information. , Angelweddingdress is ...
(Date:1/22/2015)... Orlando, Florida (PRWEB) January 22, 2015 ... up today at the 2015 PGA Merchandise Show to ... lady and incredible female amateur golfer, Arlene McKitrick. The ... career female amateur golf tournament win. She won her ...
(Date:1/22/2015)... 2015 For over 20 years, Dr. David Cruz ... Vista area has treated just about every type of injury ... And for those same twenty-plus years, the team at ... injuries with the best possible doctor. With the combined ...
(Date:1/22/2015)... Jolla, Calif. (PRWEB) January 22, 2015 ... Assemblymembers Susan Bonilla (D-Concord) and Kristin Olsen (R-Modesto) ... for their leadership in advancing biotechnology, biomedical science, ... Bonilla and Olsen each received the “2014 Life ...
Breaking Medicine News(10 mins):Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3
... HealthDay Reporter , TUESDAY, Dec. 14 (HealthDay ... years, especially women, are less likely to face the ... researchers say. But regular exercise while young only ... about 150 minutes of moderate to vigorous physical activity ...
... vaccines targeted against various types of cancer has raised ... however, is that these promising treatments are difficult to ... cellular target to stop cancer growth without inactivating the ... report a laboratory finding that has the potential to ...
... 14, 2010 Researchers at UT Southwestern Medical Center ... and normal tissue that predict survival time and potential ... "Patient responses to cancer treatment vary widely and ... Dr. David Mangelsdorf, chairman of pharmacology at UT Southwestern ...
... weapon against inoperable liver cancer is so tiny that ... to interventional radiologists at the Indiana University School of ... The glass spheres contain a radioactive element, yttrium-90, ... a very limited distance so that healthy tissue around ...
... Pallarito HealthDay Reporter , TUESDAY, Dec. 14 (HealthDay ... a key component of the new U.S. health-care reform law ... the first successful challenge to the controversial legislation. ... President Barack Obama and fellow Democrats against Republicans, will continue ...
... -- Scientists report that they have advanced their knowledge ... identifying 13 new potential variations. Tumors called pheochromocytomas ... the kidney. These tumors -- which are usually benign ... gland to produce too much adrenaline, resulting in high ...
Cached Medicine News:Health News:Regular Exercise While Young May Slow Middle-Age Spread 2Health News:Regular Exercise While Young May Slow Middle-Age Spread 3Health News:UNC scientists discover potential strategy to improve cancer vaccines 2Health News:Gene information predicts survival time, possible new treatment options for lung-cancer patients 2Health News:Y-90 radioembolization offers promise for late-stage liver cancer 2Health News:Health-Care Reform Faces Long Legal Fight 2Health News:Health-Care Reform Faces Long Legal Fight 3Health News:Health-Care Reform Faces Long Legal Fight 4
EchoScan US-3300 takes accurate axial length and corneal thickness measurements in either automatic or manual modes. It is available in a single configuration or in combination with the A scan for ma...
PremierEdge™ Stab Knives - 15°....
VISCO SHIELD Viscoelastic. Complete with 23g x 7/8" Thin Wall Cannula....
Interchangeable design allows you to select a single handpiece and change tips during the procedure. Universal connector. Disassembles for easy cleaning. Tips can rotate 360 degrees to re-orient port...
Medicine Products: